Shots:
- Alvotech has signed a settlement and license agreement with Regeneron and Bayer for Eylea 2 mg (aflibercept) biosimilar. With prior US rights effective Q4’26, Alvotech now holds worldwide manufacturing and supply rights for its commercial partners
- The settlement enables Alvotech and partners to launch the biosimilar from Jan 1, 2026, in the UK and Canada, May 1, 2026, in the EEA and other non-US markets, and Japan (excluding DME) and Nov 1, 2026, with all approved indications in Japan. Other terms remain confidential
- Alvotech’s Eylea biosimilar partners include Advanz Pharma (UK/EEA), STADA (Germany), and Biogaran (France) in the EU, and Fuji Pharma in Japan. The product is approved as Mynzepli and Afiveg in the EU, Mynzepli® in the UK, and Aflibercept BS in Japan
Ref: Alvotech | Image: Alvotech, Regeneron & Bayer | Press Release
Related News: CuraTeQ Biologics Reports Positive P-III study results for Denosumab biosimilar for postmenopausal osteoporosis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
